JP2021529173A5 - - Google Patents

Info

Publication number
JP2021529173A5
JP2021529173A5 JP2020570909A JP2020570909A JP2021529173A5 JP 2021529173 A5 JP2021529173 A5 JP 2021529173A5 JP 2020570909 A JP2020570909 A JP 2020570909A JP 2020570909 A JP2020570909 A JP 2020570909A JP 2021529173 A5 JP2021529173 A5 JP 2021529173A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cancer
nucleotide sequence
rig
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020570909A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529173A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/038323 external-priority patent/WO2019246450A1/en
Publication of JP2021529173A publication Critical patent/JP2021529173A/ja
Publication of JP2021529173A5 publication Critical patent/JP2021529173A5/ja
Pending legal-status Critical Current

Links

JP2020570909A 2018-06-20 2019-06-20 Rig−iアゴニストおよびそれを使用した処置 Pending JP2021529173A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862687606P 2018-06-20 2018-06-20
US62/687,606 2018-06-20
US201862743369P 2018-10-09 2018-10-09
US62/743,369 2018-10-09
US201962815870P 2019-03-08 2019-03-08
US62/815,870 2019-03-08
PCT/US2019/038323 WO2019246450A1 (en) 2018-06-20 2019-06-20 Rig-i agonists and treatments using same

Publications (2)

Publication Number Publication Date
JP2021529173A JP2021529173A (ja) 2021-10-28
JP2021529173A5 true JP2021529173A5 (cg-RX-API-DMAC10.html) 2022-06-10

Family

ID=68982664

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020570909A Pending JP2021529173A (ja) 2018-06-20 2019-06-20 Rig−iアゴニストおよびそれを使用した処置

Country Status (6)

Country Link
US (3) US12472198B2 (cg-RX-API-DMAC10.html)
EP (1) EP3810151B1 (cg-RX-API-DMAC10.html)
JP (1) JP2021529173A (cg-RX-API-DMAC10.html)
CN (1) CN112672748A (cg-RX-API-DMAC10.html)
CA (1) CA3110102A1 (cg-RX-API-DMAC10.html)
WO (1) WO2019246450A1 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
EP3429618B1 (en) 2016-03-16 2024-02-21 Amal Therapeutics SA Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
KR20190057345A (ko) 2016-09-21 2019-05-28 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
CN119286871A (zh) 2018-04-19 2025-01-10 查美特制药公司 合成rig-i样受体激动剂
EP3863675A4 (en) * 2018-10-09 2023-09-06 Yale University RIG-I AGONISTS AND METHODS OF USE THEREOF
CA3155202A1 (en) 2019-10-23 2021-04-29 Arthur M. Krieg Synthetic rig-i-like receptor agonists
CA3156933A1 (en) * 2019-11-04 2021-05-14 Anna Marie Pyle Rig-i innate immune receptor antagonists and methods of using same
WO2022079175A1 (en) * 2020-10-14 2022-04-21 Boehringer Ingelheim International Gmbh Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
US11786545B2 (en) * 2020-12-09 2023-10-17 Yale University Compositions and methods for treating SARS-CoV-2 infection
KR20240043747A (ko) 2021-07-02 2024-04-03 예일 유니버시티 암을 치료하기 위한 조성물 및 방법
JP2024532621A (ja) 2021-08-31 2024-09-05 イエール ユニバーシティ がんを治療するための組成物および方法
AU2023228912A1 (en) 2022-03-03 2024-09-19 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
CN114814231B (zh) * 2022-03-08 2024-08-27 上海交通大学医学院附属瑞金医院 维甲酸诱导基因i在癌症治疗中的应用
CN117379551A (zh) * 2022-07-04 2024-01-12 中国科学院上海营养与健康研究所 一种肿瘤联合治疗疗法
WO2025040743A1 (en) 2023-08-22 2025-02-27 Univerza V Ljubljani Conjugated tlr7 and rig-i agonists
WO2026039779A1 (en) 2024-08-15 2026-02-19 Yale University Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding
WO2026112449A1 (en) 2024-11-21 2026-05-28 Rigimmune Inc. Formulations

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
ES2192672T3 (es) 1996-11-18 2003-10-16 Takeshi Imanishi Nuevos analogos de nucleotidos.
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6143877A (en) 1997-04-30 2000-11-07 Epoch Pharmaceuticals, Inc. Oligonucleotides including pyrazolo[3,4-D]pyrimidine bases, bound in double stranded nucleic acids
EP1015469B2 (en) 1997-09-12 2015-11-18 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
US6127121A (en) 1998-04-03 2000-10-03 Epoch Pharmaceuticals, Inc. Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination
IL145496A0 (en) 1999-03-24 2002-06-30 Exiqon As Improved synthesis of [2.2.1] bicyclo nucleosides
ATE356824T1 (de) 1999-05-04 2007-04-15 Santaris Pharma As L-ribo-lna analoge
US6287778B1 (en) 1999-10-19 2001-09-11 Affymetrix, Inc. Allele detection using primer extension with sequence-coded identity tags
US6660845B1 (en) 1999-11-23 2003-12-09 Epoch Biosciences, Inc. Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
US20090247613A1 (en) 2002-02-20 2009-10-01 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF B-CELL CLL/LYMPHOMA-2 (BCL2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
US20070270360A1 (en) 2003-04-15 2007-11-22 Sirna Therapeutics, Inc. Rna Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (Sars) Gene Expression Using Short Interfering Nucleic Acid
CA2538169A1 (en) 2003-09-09 2005-03-17 Albert Einstein College Of Medicine Of Yeshiva University Transition state analog inhibitors of ricin a-chain
US20080293053A1 (en) 2006-12-28 2008-11-27 The Regents Of The University Of Michigan shRNA Materials and Methods of Using Same for Inhibition of DKK-1
WO2009023333A2 (en) 2007-05-17 2009-02-19 Baylor College Of Medicine Inhibition of the sh2-domain containing protein tyr-phosphatase, shp-1, to enhance vaccines
AU2009215795A1 (en) 2008-02-21 2009-08-27 University Of Kentucky Research Foundation Ultra-small RNAs as toll-like receptor-3 antagonists
US8575123B2 (en) 2008-04-11 2013-11-05 Tekmira Pharmaceuticals Corporation Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
CA2731779A1 (en) 2008-07-24 2010-01-28 Rxi Pharmaceuticals Corporation Rnai constructs and uses therof
WO2010045384A2 (en) 2008-10-15 2010-04-22 Somagenics Inc. Short hairpin rnas for inhibition of gene expression
US8563710B2 (en) 2009-04-03 2013-10-22 Biomics Biotechnologies Co., Ltd. Modified oligonucleotide and its preparation and application
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
JP2015502365A (ja) 2011-12-12 2015-01-22 オンコイミューニン,インコーポレイティド オリゴヌクレオチドのイン−ビボ送達
US10947543B2 (en) * 2013-03-13 2021-03-16 Yale University Interferon production using short RNA duplexes
CU24377B1 (es) * 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
CN106794246B (zh) 2014-08-08 2021-10-15 OncoQuest制药有限公司 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
CA3014759C (en) * 2016-02-15 2020-09-22 FKD Therapies Limited Improved interferon therapy
EP3436031A4 (en) 2016-04-01 2019-09-18 Vycellix, Inc. Novel RNA construct and method of use therefor for increasing the therapeutic effects of cytotoxic cells and stem cells
CN109715205A (zh) 2016-08-19 2019-05-03 库瑞瓦格股份公司 用于癌症治疗的rna
WO2018172546A1 (en) * 2017-03-24 2018-09-27 Rigontec Gmbh Method for designing rig-i ligands
US10710272B2 (en) 2017-12-14 2020-07-14 United Technologies Corporation Hybrid material airflow impression molds
US10736957B2 (en) 2017-12-19 2020-08-11 President And Fellows Of Harvard College Enhanced immunogenicity of mRNA with co-encoded adjuvant sequences
JP7386161B2 (ja) 2017-12-19 2023-11-24 ブレイズ バイオサイエンス, インコーポレイテッド 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
WO2019136432A1 (en) * 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
US11499157B2 (en) * 2018-01-17 2022-11-15 Nanyang Technological University Immunomodulatory small hairpin RNA molecules
CN119286871A (zh) 2018-04-19 2025-01-10 查美特制药公司 合成rig-i样受体激动剂

Similar Documents

Publication Publication Date Title
TWI784934B (zh) 抑制lpa之基因表現之組合物及方法
AU2024202093A1 (en) Peptides and nanoparticles for intracellular delivery of mrna
KR102737464B1 (ko) 안지오포이에틴-유사 3 (ANGPTL3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물, 및 사용 방법
JP7830340B2 (ja) PNPLA3の発現を阻害するためのRNAi薬、その医薬組成物、及び使用方法
JP2021533804A5 (cg-RX-API-DMAC10.html)
RU2015119409A (ru) Конъюгаты олигонуклеотидов
JP2007529224A5 (cg-RX-API-DMAC10.html)
TW201639962A (zh) Rna干擾劑
JP2023503635A (ja) Rna分子を合成する方法
EP4665854A1 (en) Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof
CN114369130A (zh) 修饰的硫代寡核苷酸及其应用
CN116077673B (zh) 一种f碱基白蛋白药物运载体系及其制备方法和用途
JP2022507425A (ja) Foxp3発現のモジュレータ
JP2022512651A5 (cg-RX-API-DMAC10.html)
US20260092281A1 (en) Methods for treatment of anemia
EP4396347B1 (en) Chimeric complex and therapeutic uses thereof
RU2022105124A (ru) Нуклеиновые кислоты для ингибирования экспрессии c3 в клетке
WO2026069321A1 (en) Nucleic acids for inhibiting expression of transferrin receptor 2
HK40113403A (en) Cyclic structured oligonucleotides as therapeutic agents
HK40129500A (en) Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof
JP2026511268A (ja) 化学修飾ヌクレオチド
HK1259063B (en) Compositions and methods for inhibiting gene expression of lpa